Phaseline

Targets › DCLRE1C

DCLRE1C (Protein artemis): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2041.

Nuclease involved in DNA non-homologous end joining (NHEJ); required for double-strand break repair and V(D)J recombination. Required for V(D)J recombination, the process by which exons encoding the antigen-binding domains of immunoglobulins and T-cell receptor proteins are assembled from individual V, (D), and J gene segments. (UniProt, Q96SD1)

Open in Phaseline: the race on DCLRE1C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisARTEGENE
Lentiviral vector-mediated ex vivo gene therapy delivering wild-type DCLRE1C cDNA to autol
DCLRE1CPhase 1Artemis (DCLRE1C ) Deficient Severe Combined ImmunodeficiencyNov 2041

Conditions

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency (1)

Modalities

other (1)

Companies

Assistance Publique - Hôpitaux de Paris (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.